Citrome L, Goldberg JF, Portland KB (noiembrie 2013). „Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed”. Journal of Affective Disorders. 151 (2): 409–17. doi:10.1016/j.jad.2013.06.027. PMID23890583.
Taavitsainen P, Anttila M, Nyman L, Karnani H, Salonen JS, Pelkonen O (mai 2000). „Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes”. Pharmacology & Toxicology. 86 (5): 215–21. doi:10.1034/j.1600-0773.2000.pto860504.x. PMID10862503.
drugbank.ca
„Selegiline”. DrugBank - Canadian Institutes of Health Research. Accesat în .
drugs.com
„Selegiline”. The American Society of Health-System Pharmacists. Accesat în .
Citrome L, Goldberg JF, Portland KB (noiembrie 2013). „Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed”. Journal of Affective Disorders. 151 (2): 409–17. doi:10.1016/j.jad.2013.06.027. PMID23890583.
Engberg G, Elebring T, Nissbrandt H (noiembrie 1991). „Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons”. The Journal of Pharmacology and Experimental Therapeutics. 259 (2): 841–7. PMID1658311.
Taavitsainen P, Anttila M, Nyman L, Karnani H, Salonen JS, Pelkonen O (mai 2000). „Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes”. Pharmacology & Toxicology. 86 (5): 215–21. doi:10.1034/j.1600-0773.2000.pto860504.x. PMID10862503.